Goldman Sachs initiated coverage of Tandem Diabetes with a Neutral rating and $46 price target The firm is bullish on the outlook for insulin pump adoption in the Type 1 diabetes population and further share gains for Tandem supported by new product cycles. However, Street numbers accurately capture this favorable growth outlook with further upside requiring higher Type 2 adoption, greater share gains, or an accelerated view on profitability, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Home Depot upgraded, Humana downgraded: Wall Street’s top analyst calls
- Tandem Diabetes initiated with an Outperform at RBC Capital
- Citi opens ‘negative catalyst watch’ on Tandem Diabetes into earnings
- App data suggests potential Q3 shipment beat from Tandem, says Morgan Stanley
- TJX downgraded, Crocs upgraded: Wall Street’s top analyst calls